Collaborative Arrangement Aggregate Sales-Based Milestone Payment

No definition available.

Name:	amrx_CollaborativeArrangementAggregateSalesBasedMilestonePayment
Namespace Prefix:	amrx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Collaborative Arrangement, Contingent Payments, Amount

+ References

No definition available.

+ Details

Name:	amrx_CollaborativeArrangementContingentPaymentsAmount
Namespace Prefix:	amrx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Collaborative Arrangement, Profit Share, Percentage

+ References

No definition available.

+ Details

Name:	amrx_CollaborativeArrangementProfitSharePercentage
Namespace Prefix:	amrx_
Data Type:	dtr-types1:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Collaborative Arrangement, Term

+ References

No definition available.

+ Details

Name:	amrx_CollaborativeArrangementTerm
Namespace Prefix:	amrx_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Collaborative arrangement, up-front payment.

+ References

No definition available.

+ Details

Name:	amrx_CollaborativeArrangementUpfrontPayment
Namespace Prefix:	amrx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

License Supply Agreement, Potential Future Milestone Payments

+ References

No definition available.

+ Details

Name:	amrx_LicenseSupplyAgreementPotentialFutureMilestonePayments
Namespace Prefix:	amrx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Percentage of ownership interest.

+ References

No definition available.

+ Details

Name:	amrx_PercentageOfOwnershipInterest
Namespace Prefix:	amrx_
Data Type:	dtr-types1:percentItemType
Balance Type:	na
Period Type:	instant

- Definition

Amount of transactions with related party during the financial reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483326/850-10-50-1

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483326/850-10-50-3

+ Details

Name:	us-gaap_RelatedPartyTransactionAmountsOfTransaction
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(2)(c)(2)(i))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(2)(c)(2)(ii))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(2)(g)(3))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1

+ Details

Name:	us-gaap_RelatedPartyTransactionLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Details

Name:	us-gaap_TypeOfArrangementAxis=amrx_KashivBioSciencesLicenseAndCommercializationAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	amrx_MilestonePaymentAxis=amrx_DevelopmentMilestonesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	amrx_MilestonePaymentAxis=amrx_RegulatoryApprovalMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RelatedPartyTransactionAxis=amrx_ResearchAndDevelopmentReimbursementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	amrx_MilestonePaymentAxis=amrx_AchievementOfAnnualCommercialMilestoneMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	amrx_MilestonePaymentAxis=amrx_InitialCommercialLaunchMilestonesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_BusinessAcquisitionAxis=amrx_KashivBioSciencesLLCMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Related Party Transactions - Narrative (Details) - USD ($) $ in Millions	1 Months Ended		3 Months Ended
	Mar. 31, 2024	Dec. 31, 2022	Mar. 31, 2024
Kashiv Bio Sciences License and Commercialization Agreement
Related Party Transaction [Line Items]
Collaborative arrangement upfront payment			$ 0.5
Collaborative arrangement aggregate sales-based milestone payment	$ 37.5
Collaborative arrangement, profit share (percent)	50.00%
Collaborative arrangement term			10 years
Kashiv Bio Sciences License and Commercialization Agreement \| Development Milestones
Related Party Transaction [Line Items]
License supply agreement, potential future milestone payments	$ 7.0
Kashiv Bio Sciences License and Commercialization Agreement \| Regulatory Approval
Related Party Transaction [Line Items]
License supply agreement, potential future milestone payments	$ 7.5
R&D Reimbursement \| Related Party \| Kashiv Bio Sciences License and Commercialization Agreement
Related Party Transaction [Line Items]
Amounts of transaction with related party		$ 2.4
Ownership interest (percent)	50.00%		50.00%
R&D Reimbursement \| Related Party \| Kashiv Bio Sciences License and Commercialization Agreement \| Development Milestones
Related Party Transaction [Line Items]
Collaborative arrangement maximum contingent payments amount			$ 10.0
R&D Reimbursement \| Related Party \| Kashiv Bio Sciences License and Commercialization Agreement \| Regulatory Approval
Related Party Transaction [Line Items]
Collaborative arrangement maximum contingent payments amount			20.0
R&D Reimbursement \| Related Party \| Kashiv Bio Sciences License and Commercialization Agreement \| Achievement Of Annual Commercial Milestone
Related Party Transaction [Line Items]
Collaborative arrangement maximum contingent payments amount			5.0
R&D Reimbursement \| Related Party \| Kashiv Bio Sciences License and Commercialization Agreement \| Initial Commercial Launch Milestones
Related Party Transaction [Line Items]
Collaborative arrangement maximum contingent payments amount			20.0
Kashiv Biosciences LLC
Related Party Transaction [Line Items]
Collaborative arrangement upfront payment	$ 14.5
Kashiv Biosciences LLC \| R&D Reimbursement \| Related Party \| Maximum
Related Party Transaction [Line Items]
License supply agreement, potential future milestone payments			$ 35.0